Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year...
Clover Biopharmaceuticals Launches AdimFlu-S, the Only Imported Quadrivalent Influenza Vaccine in China
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland...
HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...
Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Hasten Biopharmaceutical Secures Licensing Deal for LIB’s Lerodalcibep in Greater China
China-based Hasten Biopharmaceutical Co., Ltd has entered into a licensing agreement with US firm LIB...
FDA Extends Pfizer’s Comirnaty Vaccine Indication for Omicron XBB.1.5 Variant
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) an indication extension...
Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial
Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...
Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial
Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...
Wecare Medical Secures Pre-Series A Funding to Advance Brain Health Technology
Hangzhou-based Wecare Medical, a developer of brain disease diagnosis, monitoring, and treatment products, has reportedly...
Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17
The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...
China Updates Narcotics and Psychotropic Substances Catalog, Adds Three Substances
The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...
Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials
China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase...
Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds
China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA： 688131) has...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17
Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...
Merck & Co. Becomes First Multinational to Register Unit in Hainan’s Lecheng Pilot Zone
US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has officially registered a...
Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval...
ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for...
CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod
The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...
Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to...